Niagen Bioscience (NAGE) announced it has entered into a worldwide exclusive commercial license agreement with Haukeland University Hospital in Bergen, Norway. The agreement secures exclusive rights to intellectual property, know-how, and data expected to support future regulatory filings for the potential treatment of Parkinson’s Disease using the company’s patented nicotinamide riboside molecule, Niagen. Central to the agreement is access to data from the NOPARK trial, a Phase III clinical trial featuring 400 individuals with early-stage Parkinson’s.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAGE:
- Niagen Bioscience Approves Equity Plan Amendment
- Niagen Bioscience price target raised to $16 from $13 at Canaccord
- Niagen Bioscience presents results in journal Aging Cell
- Niagen Bioscience price target raised to $23 from $10 at Roth Capital
- Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’